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Thymidylate synthase (TS) represents a key enzyme in pyrimidine
biosynthesis catalyzing the reductive methylation of deoxy-
uridylate (dUMP) to thymidylate (dTMP). The transferred methyl
group is donated by 5,10-methylene tetrahydrofolate (N5,N10-
CH2FH4). This reaction provides the sole intracellular de novo
source of dTMP that is used exclusively in the biosynthesis and
repair of DNA. This unique function of TS has led to the develop-
ment of novel folate-based anti-tumour compounds that target it
specifically (Jackman and Judson, 1996).
The activity of these and other clinically used TS inhibitors
have been shown to be influenced by a number of factors,
including drug uptake and activation (Jackman et al, 1995) and
inactivation (Rhee et al, 1993). Amplification of the TS gene is an
important determinant of acquired resistance to TS inhibitors in
vitro (Jackman et al, 1986, O’Connor et al, 1992; Copur et al,
1995; Freemantle et al, 1995; Jackman et al, 1995). Modulation of
TS expression by using antisense TS RNA has recently been
reported to influence cell sensitivity to fluoropyrimidines and
antifolates (Kobayashi et al, 1995; Ju et al, 1998). In the clinic, a
correlation between both TS protein and TS gene transcript levels
of colorectal, gastric and breast carcinoma and response to 5-FU-
based chemotherapy for advanced disease (Johnston et al, 1994;
1995; 1997; Lenz et al, 1995; Pestalozzi et al, 1997) has been
reported. However, no link was found between TS expression in
primary tumour and response to TS-directed chemotherapy for
subsequent metastatic disease (Findlay et al, 1997). This could be
explained by different levels of TS expression in metastatic lesions
compared to primary tumours. However, the expression of other
proteins involved in drug uptake and metabolism, or in down-
stream events such as DNA repair and cell death mechanisms, may
also have a role to play in determining sensitivity to TS inhibition.
Inhibition of TS leads to rapid depletion in the dTTP pool and
an expansion in the dUMP pool (Jackson et al, 1983; Aherne et al,
1996a). This in turn may be phosphorylated to dUTP. These dNTP
perturbations are thought to be important in the eventual loss of
cell viability following TS inhibition. As DNA polymerase does
not distinguish between dUTP and dTTP, the accumulation in
dUTP during dTTP depletion promotes the misincorporation of
the fraudulent base, uracil, into DNA where it is subsequently
excised by uracil-DNA-glycosylase to form an apyrimidinic site.
If dTTP remains depleted, dUTP may be reinserted and a futile
cycle of excision repair and re-insertion will occur leading to
lethal DNA damage. This ‘misincorporation theory’ (reviewed in
Aherne and Brown, 1999) has provided a possible mechanism of
action promoting cell death in dTTP-depleted cells (Curtin et al,
1991; Canman et al, 1993).
dUTPase is an ubiquitous enzyme that is responsible for the
hydrolysis of dUTP to dUMP thereby minimizing the misincorpo-
ration of dUTP into DNA (Lindahl, 1979). Recent studies using
tumour cells with genetically increased dUTPase activity that
exhibit enhanced resistance to FdUrd have further supported the
belief that dUTPase, the main regulator of dUTP pools, serves an
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al, 1994). Thus, we have studied the expression of this enzyme in
different human tumour cell lines and addressed the relationship
between dUTPase expression and cellular response to TS inhibi-
tion.
Historically, the fluorinated pyrimidines have been used exten-
sively to study the critical events leading from TS inhibition to cell
death (Aherne and Brown, 1999). However, since metabolites of
these compounds may be incorporated into nucleic acids the
cellular effects of thymineless death cannot necessarily be attribut-
able solely to a thymineless state. ZD9331 is a quinazoline-based
antifolate-specific TS inhibitor (Jackman et al, 1997) currently
under clinical development. Since ZD9331 acts only at the TS loci,
this compound has provided an appropriate tool to study the
cellular effects of TS inhibition. In addition, the lack of folylpoly-
glutamylsynthetase (FPGS) substrate activity for ZD9331 prevents
its cellular retention (due to a lack of polyglutamate formation),
hence use of ZD9331 also permits greater control of the duration
of TS inhibition (Aherne et al, 1996b).
MATERIAL AND METHODS
Materials
All standard laboratory chemicals used in this study were of
AnalaR grade and purchased either from British Drug Houses
(BDH, Poole, Dorset, UK) or from Sigma (Poole, Dorset, UK).
ZD9331, raltitrexed (RTX, Tomudex, ZD1694), nolatrexed
(Thymitaq, AG337 (Webber et al, 1996)) and CB300179 (Skelton
et al, 1998) were synthesized at Zeneca Pharmaceuticals
(Macclesfield, Cheshire, UK). ‘Tomudex’ is a trademark. Property
of Zeneca Limited, part of AstraZeneca. ZD9331 and RTX were
prepared in 0.15 M sodium bicarbonate (NaHCO3), AG337 and
CB300179 were dissolved in 100% dimethysulphoxide (DMSO)
to give a 20 mM solution and solutions were filter sterilized.
Deoxythymidine 5′− triphosphate, [methyl-3H] tetra sodium salt
(NET-221X-specific activity 78 Ci mmole–1) was purchased from
New England Nuclear (NEN) Research Products. [5-3H]-
deoxyuridine 5′ -monophosphate, ammonium salt (TRK287-
specific activity 15.4 Ci mmole–1) and [3H] deoxyuridine
5′ -triphosphate (TRK 351-specific activity 22 Ci mmol–1) were
obtained from Amersham International plc (Little Chalfont,
Bucks, UK).
Cell culture
The human lung carcinoma cell lines A549 (squamous), CORL23
(large cell), MOR (adenocarcinoma) and HX147 (large cell) were
maintained in DMEM tissue culture medium (Gibco, Paisley,
Scotland) and 10% heat inactivated dialysed fetal bovine serum
(FBS) (Imperial Laboratories, Andover, Hants, UK) supplemented
with 2 mM glutamine, 50 µ g ml–1 gentamycin, 2.5 µ g ml–1 fungi-
zone, 10 µ g ml–1 insulin and 0.5 µ g ml–1 hydrocortisone, at 37° C in
air containing 5% CO2. The doubling times of these cell lines 
were 18, 28, 23, and 25 h respectively. All cells were routinely
subcultured once a week. The cells were counted using a haemo-
cytometer (Neubauer Weber, UK). The W1L2 human lymphoblas-
toid cell line was grown in suspension in RPMI 1640 containing
20 mM HEPES without NaHCO3 and supplemented with 10%
heat inactivated (56° C, 30 min) dialysed FBS (Imperial
Laboratories or ICN Flow, Thames Oxfordshire UK), 20 µ g ml–1
gentamycin, 2 mM L-glutamine and 0.5 µ g ml–1 fungizone. Cells
were maintained at 37° C. W1L2-resistant sub-lines (W1L2R1694
(Jackman et al, 1995), and W1L2:C1 (O’Connor et al, 1992) that
overexpress TS by 500- and 200-fold respectively, and W1L2R179
(Kobayashi et al, 1995) and W1L2R9331 (unpublished results) both
with a ~20-fold increase in TS activity) were maintained in
medium containing the selective compound (5 µ M RTX, 50 µ M
ICI198583, 5 µ M CB300179, or 0.02 µ M ZD9331) until 2–3
weeks prior to experimentation, when they were grown in drug-
free medium (DFM) in the same way as the parent line. Cell
numbers were determined using a Coulter Counter, model ZM. All
cell lines were free of mycoplasma during the course of these
studies.
Growth inhibition studies
The human lung tumour cell lines were seeded at 1–2 × 103 cells
per well in a 96-well tissue culture plate (Falcon) and left to adhere
overnight prior to drug exposure. Cells were exposed to drugs for
120 h before cell growth inhibition analysis using the MTT assay.
For 24 h IC50 experiments, drug was removed 24 h after drug
exposure using three PBS washes (37° C). The cells were incu-
bated for a further 120 h in 200 µ l culture medium before analysis
using MTT. 50 µ l MTT (5 mg ml–1) (Sigma) was added to each
well, the plates incubated at 37° C for 4 h and the medium aspi-
rated. The resulting formazan crystals were dissolved using 100 µ l
of DMSO (BDH), the plates shaken for 10 min on a plate shaker
and the absorbance measured at 540 nm on a Multiscan plate
reader (Labsystems).
Intracellular dTTP, dUMP and dUTP
The human lung tumour cell lines were seeded in T-80 tissue
culture flasks (Falcon) in triplicate (5 × 105 cells 10 ml–1) and left
to reach 50–60% confluency before treatment. Cells were exposed
for 4, 16 or 24 h to medium containing ZD9331. After drug expo-
sure, the medium was aspirated and flasks flooded with 1 ml ice-
cold 0.4 M perchloric acid (PCA), the cells vortexed vigorously
and left on ice for 30 min with intermittent vortexing before
centrifugation (4° C, 20 min) at 3000 rpm (1500 g). The super-
natants were transferred to chilled Eppendorf tubes and neutralized
with a half volume of 0.73 M KOH in 0.16 M KHCO3. The
neutralized samples were left on ice for 30 min then centrifuged at
10 000 rpm (2500 g) for 10 min (4° C) and the resulting super-
natant was stored at –70° C until further treatment.
Thawed cell extracts were treated with sodium periodate to
remove NTPs and intracellular dUTP, dTTP and immunoreactive
‘dUMP’ measured in duplicate as previously described (Aherne et
al, 1996a). Cell numbers were determined from parallel flasks and
cellular dUTP, dTTP and ‘dUMP’ were expressed as pmole per 106
cells.
Measurement of intracellular ZD9331
Duplicate flasks of human lung cancer cells in logarithmic growth
(50–60% confluency) were exposed to ZD9331 for 4 or 24 h and
the cells washed twice with cold PBS. Cells were harvested by
scraping into 1 ml of ice cold PBS before centrifuging for 5 min at
2500 rpm (600 g) (4° C). The cell pellet was re-suspended in 1 ml
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(Soniprep 150 MSE), then centrifuged for 5 min (4° C, 2500 rpm).
The supernatant was removed and stored at –20° C. Intracellular
ZD9331 concentrations were determined using an antibody coated
ELISA (Jackman et al, 1997).
Western immunoblot analysis
Western blot analysis was performed according to standard proto-
cols and the protein bands of interest were probed using either a
rabbit polyclonal antibody (affinity purified) to recombinant
human dUTPase (Ladner et al, 1996) or an affinity purified anti-
serum to human recombinant TS (Aherne et al, 1997).
Recombinant proteins were used as controls (data not shown).
Visualization of the protein bands was performed using enhanced
chemiluminescence (ECL) reagents (Amersham International).
TS assay
The method for the measurement of TS activity has been described
previously (Calvert et al, 1980). The assay is based on the release
of 3H in the form of H2O from 5-[3H]dUMP by TS. Small Dowex
columns (anion exchanger) were utilized to separate the product
([3H] H2O) from the substrate (5-[3H]dUMP). Briefly, cells in log
phase (~1 × 107) were resuspended in 2 ml of TS buffer 
(0.125 mM KH2PO4, 3 mM dithiothreitol, pH 7.4). The cell
suspension was then sonicated at 12 microns for three separate 10
s intervals on ice then centrifuged for 1 h at 19 000 rpm (50 000 g)
at 4° C. TS activity was measured in the resulting supernatant in a
0.5 ml incubation mixture containing: 0.2 ml of assay mix
(containing 10 µ l [3H]dUMP (~0.5 µ Ci), 2.5 µ l 10 mM ‘cold’
dUMP, and 187.5 µ l H2O), and 0.05 ml 2 mM L-N5 N10-CH2FH4.
The reaction was allowed to proceed for 1 h at 37° C and termi-
nated by the addition of 1 ml of iced water. The sample was than
passed down a 3 × 0.5 cm Dowex column and eluted with a further
2 ml of iced water. The amount of radioactivity in the effluent was
counted using scintillation counting. Protein estimations were
performed using the Pierce BCA kit according to manufacturer’s
instructions. TS activity was calculated from three supernatant
dilutions (linear up to the highest concentration used) with and
without FH4, and expressed as nmole product per mg protein per h.
dUTPase assay
The dUTPase assay (Caradonna and Adamkiewicz, 1984) is based
on the formation of [3H]dUMP from [3H]dUTP. Separation of radi-
olabeled dUMP, dUDP and dUTP after the reaction was achieved
by thin layer chromatography (TLC). Briefly, exponentially
growing cells (~1 × 106) were resuspended in 0.5 ml dUTPase
extraction buffer containing 50 mM Tris (pH 7.6 at 37° C) and 
2 mM DTT. The cells were frozen to –80° C for 10 min, thawed,
sonicated twice for 30 s (10 microns) then centrifuged for 10 min
at 18 000 rpm (9000 g) (4° C). The resulting supernatant was then
assayed for dUTPase. Protein estimations were performed using
the Pierce BCA kit according to manufacturer’s instructions. 1 unit
of dUTPase activity was expressed as nmole dUTP hydrolysed
min–1 mg–1 of protein at 37° C.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
software. The Spearmans non-parametric correlation test was used
to determine the linear association between the rank order of two
variables. The square of the correlation coefficient (r2) calculated
from this test quantified the direction and magnitude of the corre-
lation. The paired Students t-test and one-way ANOVA were used
to investigate differences between variables.
RESULTS
Growth inhibitory activity of ZD9331
The effect on cell growth over a 120 h period of continuous expo-
sure to ZD9331 in the human lung carcinoma cell line panel is
shown in Table 1. The concentration of ZD9331 required for inhi-
bition of growth by 50% (IC50) varied up to 20-fold. The least
sensitive cell line was A549 (IC50 = 70 ± 14.7 nM) which
compared to an IC50 of 3.2 (1 nM for the most sensitive cell line,
CORL23). A similar pattern of sensitivity was obtained with the
highly polyglutamatable TS inhibitor, RTX, and with the lipophilic
TS inhibitor, AG337 (Table 1). A549 cells were ~8- and ~20-fold
less sensitive to RTX and AG337 respectively than CORL23 and
MOR cells.
All cell lines were more sensitive to RTX than ZD9331
(ZD9331 IC50: RTX IC50 ratio was 2:9). Since RTX and ZD9331
both use the RFC for cell entry and both target TS, the higher rela-
tive sensitivity of A549 and MOR cells to ZD1694 could indicate
higher FPGS activity compared to CORL23 and HX147 cells.
AG337 is at least 100-fold less active compared to ZD9331, an
observation which can be accounted for by its lack of active
cellular uptake and lower TS potency (Webber et al, 1996).
The pattern of sensitivity following a 24 h exposure to ZD9331
was different to that following a 120 h exposure (Table 1) and
there was only a 3-fold variation in IC50 concentrations. MOR cells
which were 10-fold more sensitive than A549 cells after a 120 h
exposure, were 2.5-fold less sensitive following a 24 h exposure.
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Table 1 ZD9331, ZD1694 and AG337 IC50 values (mean ± SD) in four human lung tumour cell lines
Cell line ZD9331 RTX ZD9331 ZD9331 ZD9331 AG337
IC50:RTX IC50
120 h IC50 nM 120 h IC50 nM ratio 24 h IC50 nM 24 h:120 h 120 h IC50 µ M
IC50 ratio
A549 70 ± 14.7 8.1 ± 4.6 8.6 111 ± 25 1.6 15.5 ± 5
HX147 14 ± 54   ± 1.2 3.5 173 ± 75 12.3 5.53 ± 0.64
CORL23 3.2 ± 1 1.4 ± 0.41 2.3 n/e n/e 0.51 ± 0.3
MOR 7.3 ± 1.7 1 ± 0.45 6.7 276 ± 25 38 0.71 ± 0.2
Growth inhibition was determined using MTT assay (three separate determinations in quadruplicate); n/e = not evaluableThe 24 h IC50:120 h IC50 ratio is shown in Table 1. The high ratio
for MOR cells (38) was in contrast to that for A549 cells (1.6)
which appeared to be more equally affected by a short and
prolonged exposure to the drug.
Intracellular concentrations of ZD9331
To establish that variations in sensitivity to ZD9331 were not due
to differences in drug accumulation, intracellular drug levels were
measured following a 4 h and a 24 h exposure to 1 µ M ZD9331
(Table 2). ZD9331 concentrations at 4 h varied ~2-fold (7.4 ± 1.1
to 16.5 ± 11 pmole 10–6 cells) and were not significantly different.
At 24 h drug levels were similar to those obtained after a 4 h expo-
sure to ZD9331. A549 cells had the highest drug concentrations
(13.3 ± 3.9 pmole 10–6 cells) and MOR cells the lowest (6.3 ± 1.3
pmole 10–6 cells) but this difference was not significant (P > 0.05).
As may have been expected there was no relationship between
intracellular levels of ZD9331 and sensitivity to either short (24 h)
or prolonged (120 h) exposure to ZD9331.
TS protein expression and activity
There was a 26-fold variation in TS protein expression (Figure 1)
in the lung cell line panel as determined by Western blotting. The
relative volume of integration obtained by densitometry (n = 2)
was 13, 338, 45, and 60 for CORL23, HX147, MOR, and A549
cells, respectively. TS protein expression and TS activity (Table
3) correlated well (r2 = 0.88, P = 0.05). HX147 cells had signifi-
cantly (P < 0.001) higher TS activity than MOR and CORL23
cells.
As the number of cell lines was small it was not possible to
correlate TS activity with sensitivity to ZD9331 at 24 h or 120 h.
However, it can be observed that although the two most sensitive
cell lines following 120 h exposure to drug (CORL23 and MOR)
had low TS activity, HX147 cells with the highest TS activity were
5-fold more sensitive to ZD9331 than A549 cells. However,
HX147 cells accumulated more ZD9331 in 24 h than A549 cells.
Effect of ZD9331 on dTTP, dUMP and dUTP pools
All cells showed a significant (at least P < 0.05) reduction (> 80%)
in dTTP pools by 4 h (Table 4) confirming TS inhibition following
1 µ M ZD9331. Interestingly, at 4 h dTTP depletion in HX147 cells
(43% control) was significantly less (P < 0.001) than in A549
(13% control) and MOR (11% controls) cells and in CORL23 cells
(21%, P = <0.01). This may reflect the finding that HX147 had
high TS activity and protein expression. Conversely, dTTP deple-
tion was greatest in the cell line (MOR) with the lowest TS
activity. Following 16 h and 24 h in drug, dTTP pools were
depleted further in all cell lines except A549. A significant 
(P < 0.0001) rise in ‘dUMP’ pools was measured in all cells.
In contrast, large differences between cell lines in dUTP accu-
mulation were observed (Figure 2). By 4 h, A549 cells had accu-
mulated a significant (P < 0.0001) amount of dUTP (6.2 ± 0.9
pmole 10–6 cells) (control value in all cell lines was ~1 pmole 10–6
cells). By 24 h, the pool size increased to 57 ± 20 pmole dUTP 10–6
cells. The accumulation of dUTP in HX147 cells was slower than
that in A549 cells, but by 24 h the pool had increased to 
17 ± 8.6 pmole dUTP 10–6 cells. In contrast, MOR and CORL23
cells did not accumulate dUTP after ZD9331 treatment. Indeed,
even at a 10-fold higher dose of ZD9331 (10 µ M, 24 h) dUTP
pools were only moderately increased (4.3 pmoles 10–6 cells) in
MOR cells. This is in contrast to A549 cells in which dUTP pools
were increased to 123 pmoles 10–6 cells under the same conditions
(data not shown).
If the extent of dUTP accumulation were an important determi-
nant of cellular response to ZD9331, then one would expect to
observe a negative association between dUTP accumulation and
IC50. Although only three cell lines were included, this expected
association was observed with 24 h IC50 values (Figure 3) but not
the 120 h continuous exposure sensitivity to ZD9331.
dUTPase protein expression and activity
A 17-fold variation in dUTPase protein expression was observed
in the lung tumour cell line panel (Figure 4A). dUTPase activity
(Table 3) correlated (P = 0.03, r2 = 0.94) with dUTPase protein
expression (quantified using densitometry) (Figure 4B). MOR
cells had significantly (P < 0.001) higher levels of dUTPase
activity than HX147 and A549 cells. No association was observed
between sensitivity (24 h or 120 h IC50) to ZD9331 and dUTPase
activity. Although a statistically significant correlation was not
observed between dUTPase activity and the amount of dUTP
dUTPase and sensitivity to ZD9331 795
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Table 2 Intracellular ZD9331 levels following exposure to 1 µ M ZD9331
measured by ELISA
Cell line ZD9331 pmole 10–6 cells ZD9331 pmole 10–6 cells
(4 h) (24 h)
A549 16.5 ± 11 13.3 ± 3.9
HX147 14.4 ± 6.8 11.6 ± 6.0
CORL23 10.6:6.9 8.7:7.1
MOR 7.4 ± 1.1 6.3 ± 1.3
Mean ± SD of three separate experiments in duplicate except CORL23
where n = 2 in duplicate
12345
36kDa-
Figure 1 TS protein expression in four human lung tumour cell lines
determined by Western blotting. Lane 1 Recombinant TS; Lane 2 CORL23;
Lane 3 HX147; Lane 4 MOR; Lane 5 A549. Expression was quantified using
densitometry
Table 3 Activity of TS and dUTPase in four human tumour cell lines
TS activity dUTPase activity
Cell line nmole product h–1 mg–1 nmole dUTP
protein hydrolysed min–1 mg protein–1
A549 2.9 ± 0.9 5.0 ± 2.0
HX147 6.3 ± 0.5 1.2 ± 0.15
CORL23 0.67:1.1 9.0:6.0
MOR 0.43 ± 0.12 17.2 ± 4.8*
Values are mean ± SD of three experiments in triplicate (except CORL23
where n = 2); *dUTPase activity in MOR cells was significantly (P < 0.001)
higher than HX147 and A549 cellsformed, the two cell lines that did not accumulate dUTP (MOR
and CORL23) had the highest dUTPase activity. dUTPase protein
expression showed a similar wide variation in a panel of six
human colon tumour cell lines (data not shown).
dUTPase expression in W1L2-resistant cell lines
The dUTPase expression in four W1L2 cell lines with acquired
resistance to different TS inhibitors was also studied. A 5.6- and 2-
fold increase in dUTPase protein expression was observed in
W1L2R1694 and W1L2R300179-resistant cell lines respectively
(Figure 5A). Increased expression of dUTPase protein in these
lines was associated with an increase in dUTPase activity. A
significant (P < 0.01 and P < 0.05) increase (2.3-fold and 2.7-fold
compared to the parent cell line) in dUTPase activity was
measured in W1L2R1694 and W1L2R300179, respectively (Figure
5B). Protein expression in W1L2:C1 was similar to that of W1L2
itself. W1L2R9331, which also showed no increase in dUTPase
protein by Western blotting, had a similar level of dUTPase
activity as the parent line.
DISCUSSION
The aim of this study was to investigate the role of dUTPase
expression in cellular response to TS inhibition. Four human lung
carcinoma cell lines have been characterized with respect to
sensitivity to the non-polyglutamatable TS inhibitor ZD9331, TS
expression and activity, dUTPase expression and activity, and
dNTP pool perturbations following ZD9331. The relative sensi-
tivity of the cell lines to other TS inhibitors such as RTX and
AG337 that have different biochemical profiles to ZD9331 has
also been determined.
The 20-fold variation in sensitivity to ZD9331 (120 h exposure)
in the four human lung tumour cell lines was not associated with
differences in drug accumulation. Also, the ranking of cell sensi-
tivity to AG337, which does not rely on the RFC for cell entry, was
the same as for ZD9331. The pattern of sensitivity to RTX also
mirrored that seen with ZD9331, except that the difference in the
continuous exposure IC50 value between the least sensitive (A549)
and most sensitive (CORL23) cell line was not as great. A549 and
MOR cells were relatively less sensitive to ZD9331 than RTX
compared to CORL23 and HX147 cells. Response to AG337 may
more closely reflect the effects of TS inhibition than response to
RTX as AG337 has no requirement for the RFC or FPGS (Webber
et al, 1996). It appears likely that a higher FPGS activity may
account for the high relative sensitivity of A549 and MOR cells to
RTX.
The 120 h continuous exposure IC50 value for ZD9331 in A549
cells was similar to its 24 h IC50 value (ratio = 1.6). This was in
contrast to HX147 and MOR cells with 24 h IC50:120 h IC50 ratios
of 37 and 12.3 respectively. This would suggest that there is a crit-
ical event(s) that causes significant growth inhibition in the first 24
h of ZD9331 treatment in A549 cells, whereas with MOR and
HX147 cells a longer duration of drug exposure and TS inhibition
appears to be necessary before this lesion(s) occurs.
Alternatively, A549 cells may be less sensitive to events that
occur later during prolonged periods of dTTP depletion following
exposure to ZD9331. Thus, the duration of TS inhibition required to
cause a significant growth inhibitory response is cell line-dependent
796 SD Webley et al
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Table 4 dTTP and ‘dUMP’ pools following 1 µ M ZD9331 in four human lung tumour cell lines
dTTP (pmole 10–6 cells) dUMP (pmole 10–6 cells)
Cell line 0 h 4 h 16 h 24 h 0 h 4 h 16 h 24 h
A549 35.0 ± 7.9 4.5 ± 0.43 4.6 ± 1.2 5.7 ± 2.6 63.5 ± 16 184 ± 12 1673 ± 622 2899 ± 529
HX147 31.6 ± 8.7 13.5 ± 1.8 8.5 ± 2.9 3.1 ± 1.2 58.0 ± 14 187 ± 14 201 ± 61 1331 ± 377
CORL23 30.0 ± 2.4 6.3 ± 2.4 1.0 ± 03 1.6 ± 0.5 66.0 ± 3.4 361 ± 135 2648 ± 550 1848 ± 687
MOR 29.3 ± 3.1 3.15 ± 1.1 2.2 ± 1.8 1.7 ± 0.7 35.7 ± 9.3 135 ± 3.1 394 ± 113 1881 ± 383
Mean ± SD values are shown (three experiments in duplicate)
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Figure 2 Accumulation of dUTP following 1 µ M ZD9331 in four human lung
tumour cell lines: A549 (  ), HX147 (*), MOR (  ) and CORL23 (  ). 
Mean ± SD of three experiments carried out in duplicate. A549 and HX147
accumulated significant (P < 0.0001 and P < 0.05 respectively) levels of
dUTP by 4 h and 16 h respectively
Figure 3 Relationship between IC50 (24 h) and dUTP accumulationand possibly reflects the degree and pattern of dNTP perturba-
tion. This in turn may be influenced by the inherent activity of
key enzymes in the DNA synthetic pathway such as TS and
dUTPase.
A high association (P = 0.05) between TS protein and TS
activity in the four lung cell lines was found. A correlation
between these parameters has been reported previously (Estlin et
al, 1997) but significance was only reached when two groups of
cells (11 cell lines in total) were analysed together. It is generally
accepted that both in vitro acquired and clinical resistance to TS
inhibitors are commonly associated with overexpression of TS
(Jackman et al, 1986; 1995; O’Connor et al, 1992; Johnston et al,
1994; 1995; 1997; Freemantle et al, 1995; Lenz et al, 1995;
Pestalozzi et al, 1997). As may have been anticipated, the two
most sensitive cell lines following a 120 h exposure (MOR and
CORL23) had the lowest TS activity. However, HX147 was 5-fold
more sensitive to a 120 h exposure to ZD9331 than A549 but had a
higher TS activity (2-fold). Taken together, no overall correlation
was observed between TS activity and sensitivity to both
prolonged and short exposure to ZD9331. A lack of correlation
between TS activity and sensitivity to AG337 in human tumour
cell lines has been reported previously (Estlin et al, 1997). In a
panel of 13 non-selected colon cancer cell lines TS activity was the
best predictor of sensitivity to 5FU and 5FU/LV exposure,
although for antifolates determinants of sensitivity were multifac-
torial (van Triest et al, 1999). In vivo studies have shown that the
extent of TS inhibition affects tumour response to 5FU (Spears et
al, 1984). However, depletion of dTTP pools (> 80%) (and a
simultaneous increase in deoxyuridylate) following 1 µ M ZD9331
showed that TS had been substantially inhibited by 24 h in all cell
lines. Interestingly, in the two most sensitive lines, MOR and
CORL23, dTTP had been depleted to a greater extent (~5%) than
in the other two lines (10–16%).
Most of the early studies in eukaryotic cells investigating the
role of dUTPase expression in cellular response to TS inhibition
used mainly lymphoblastic and leukaemic cell lines (Aherne and
Brown, 1999). Interpretation of these results is difficult since cells
of haematopoietic origin have high dUTPase activity (Strahler et
al, 1993) and do not accumulate large quantities of dUTPase
following TS inhibition. dUTPase expression varied considerably
in the human lung tumour cell lines studied here and similar results
were observed with a panel of colorectal tumour cell lines (data
not shown). dUTPase activity significantly correlated with protein
expression in the lung tumour cell lines. Earlier studies have
reported wide variations in dUTPase activity between tumour
types (Beck et al, 1986; Strahler et al, 1993). There was a striking
difference between dUTP accumulation in the lung tumour cell
lines following ZD9331 treatment. A549 and HX147 cells accu-
mulated significant quantities of dUTP whereas neither MOR nor
CORL23 cells accumulated dUTP under the same conditions. The
increase in the dUTP pool in A549 cells was comparable with that
described using CB3717 (Curtin et al, 1991). Although no statis-
tical correlation was found between dUTP accumulation and
dUTPase activity, MOR and CORL23 had higher levels of enzyme
than A549 and HX147. A non-proportional relationship between
the extent of dUTP accumulation and total cellular dUTPase
activity has been reported previously (Canman et al, 1993). It was
suggested that this could be due to a number of factors including
dUTPase and sensitivity to ZD9331 797
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Figure 4 (A) dUTPase protein expression in human lung tumour cell lines.
Lane 1 A549; Lane 2 MOR; Lane 3 HX147; Lane 4 CORL23. (B) Correlation
between dUTPase activity and dUTPase protein expression. dUTPase
activity is the mean ± SD of three experiments in triplicate (except CORL23,
n = 2). dUTPase activity in MOR cells was significantly (P < 0.001) higher
than HX147 and A549 cells. Densitometry readings (volume of integration)
are the mean of two separate observations
Figure 5 (A) dUTPase protein expression in W1L2 resistant cell lines. Lane
1 W1L2 parent line; Lane 2 W1L21694; Lane 3 W1L2:Cl; Lane 4 W1L29331;
Lane 5 W1L2300179. (B) dUTPase activity in W1L2 resistant cell lines (three
experiments in duplicate). *P < 0.05; **P < 0.01the non-homogeneous distribution of dUTP or dUTPase, non-
linear enzyme kinetics and the accumulation of dUTP over time.
Variations in deoxyuridine efflux may also exist between cell
lines.
Depletion of dTTP is a lethal event but a prolonged period (at
least a generation’s time) is required for this to occur (Cohen,
1971; Houghton et al, 1994). If dUTP misincorporation is also an
important event then a cell line with a relatively low dUTPase
activity would be predicted to require a shorter duration of
exposure to TS inhibitors for a lethal event to occur. An inverse
relationship between intracellular dUTPase levels (which
corresponded with the extent of dUTP/dTTP ratio elevation) and
MTX cytotoxicity among various cell types has been reported
(Beck et al, 1986). A similar trend between dUTP accumulation
and sensitivity to ZD9331 was found in this study but only when
the cells were exposed to drug for 24 h.
The E. coli dUTPase transfected HT29 human colon tumour cell
line dutE7 with a ~5-fold increase in dUTPase delayed the cyto-
toxic effects of FdUrd (Canman et al, 1994). dutE7 is also signifi-
cantly less sensitive to ZD9331-induced cytotoxicity following a
24 h exposure compared to its neotransfected control (Brown et al,
1997). This reduced sensitivity was associated with a significantly
(P < 0.05) lower dUTP pool. However, following a 48 h exposure
to ZD9331, no difference in survival between the cell lines was
found. A similar observation has been reported using CB3717 and
MTX (Parsels et al, 1998). Interestingly, they also reported that the
expression of E. coli dUTPase in a HuTu80 gastrointestinal
tumour cell line did not protect from FdUrd-induced DNA damage
or cytotoxicity. The relatively high endogenous dUTPase activity
could already be suppressing dUTP pools and it is likely that 
the effects of TS inhibition in HuTu80 cells, like MOR cells, is
largely dUTP-independent. Lowering dUTPase activity by stable
transfection of a dUTPase antisense expressing construct of the
DUT-N open reading frame into HT29 cells resulted in increased
dUTP accumulation, DNA damage and cytotoxicity of FdUrd
(Ladner and Caradonna, 1997). The sense construct (S-4) like
dutE7, was significantly less resistant to FdUrd treatment.
It is interesting that in two W1L2 cell lines with acquired resis-
tance to TS inhibitors, an approximately 3-fold increase in
dUTPase activity was observed in addition to amplified TS
expression. To the best of our knowledge, this is the first time that
this has been documented and suggests that dUTPase in some cell
lines could be under selective pressure when exposed to TS
inhibitors. This observation provides further support for the
importance of dUTPase activity in mediating the effects of TS
inhibition.
The results presented here show that sensitivity to ZD9331 in
four human tumour cell lines may be affected by a number of
factors including drug accumulation, TS activity and dTTP deple-
tion. A clear correlation with any one factor was not obtained but
this finding was probably confounded by the small number of cell
lines in the panel. The observation that a large accumulation of
dUTP was associated with increased sensitivity to a 24 h expo-
sure to ZD9331 in a cell line with low dUTPase activity is consis-
tent with previous results using dUTPase sense and antisense
transfection experiments. The overexpression of dUTPase in
some W1L2-resistant cell lines suggests that the activity of
dUTPase may be important in protecting the cell against the
effects of TS inhibition. Factors downstream of dNTP perturba-
tion are also likely to play a role in determining response to TS
inhibition in cells with different genetic backgrounds. These
include the extent of DNA damage and repair, the involvement of
oncogenic proteins such as bcl-2 (Fisher et al, 1993) and K-Ras
(Houghton et al, 1998) and the ability to initiate cell death path-
ways (Houghton et al, 1997).
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